<DOC>
	<DOCNO>NCT00542165</DOCNO>
	<brief_summary>To collect daily practice condition , clinical data change sexual function new formulation alfuzosin ( Xatral XL® ) administer daily patient low urinary tract symptom ( LUTS ) suggestive prostatic hypertrophy</brief_summary>
	<brief_title>Multicenter Prospective Study Changes Sexual Function Following Treatment With Alfuzosin ( Xatral XL® ) Patients With Benign Prostate Hypertrophy</brief_title>
	<detailed_description />
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>male patient suffer LUTS last 6months male patient age 50 year old continuous active partner Primary hypogonadism neuropathy patient History prostate surgery Patients prostate cancer History organ surgery organ damage pelvis History myocardiac infarction , stroke , life threaten arrythmia within last 6 month Patients haematuria cause reason except BPH Patients uncontrolled hypertension spite treatment antihypertensive agent History malignant tumor within last 5 year Patients currently control medication erectile dysfunction Patients administer androgen antiandrogen Patients treat psychiatric disorder depression Combination alpha1blockers Patients previously improve alpha1blocker treatment Known hypersensitivity alfuzosin History postural hypotension syncope Hepatic insufficiency Unstable angina pectoris The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>